Elevance Health (ELV) Up 12.6% Since Last Earnings Report: Can It Continue?
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?
ELV - Elevance Health Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$401.81
DETAILS
HIGH:
$498.00
LOW:
$331.00
MEDIAN:
$403.50
CONSENSUS:
$401.81
UPSIDE:
1.80%
Stock News
AI Is Coming for Pharmacy Benefit Managers: Potential Winners and Losers
Pharmacy benefit managers (PBMs) sit at the chokepoint of U.S. drug distribution.
Is ELV Undervalued? DCF Says Worth $643
On May 19, 2026, we present a detailed DCF analysis for Elevance Health Inc (ELV), a company currently trading at $394.07. The stock has shown a strong price pe
Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript
Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript
A Look at Elevance Health Inc (ELV) After 4.0% Gain -- GF Value $518.29 vs Price $393.30
On May 12, 2026, Elevance Health Inc (ELV) shares rose 4.0% today, bringing the current price to $393.30. The stock has experienced a 52-week range between $273
Is ELV Undervalued? DCF Says Worth $643
On May 12, 2026, we present a DCF analysis for Elevance Health Inc (ELV), a company currently trading at $381.75. The stock has shown mixed performance, with a
Is ELV Undervalued? DCF Says Worth $643
On May 08, 2026, we conducted a DCF analysis for Elevance Health Inc (ELV) to assess its intrinsic value in the context of its recent price performance. Over th
Major health insurers show signs of recovery – but a key test looms
Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But analysts caution that insurers have incomplete data on medical costs in the first quarter due to a lag in claims processing, which sets up the second quarter as the real proving ground.
This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how
Don Lair writes about options income, dividend strategy, and the kind of boring-but-durable investing that actually funds retirement.
Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care
INDIANAPOLIS--(BUSINESS WIRE)--Despite growing awareness, mental health concerns remain difficult to navigate and often lead to avoidable crises, costly emergency room visits, and long-term strain on individuals, families, and an already overburdened healthcare system. With nearly one in five Americans experiencing a diagnosable mental health condition each year, the need for funding and systemic improvement has never been greater. That's why Elevance Health is focused on addressing some of the.
Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, along with its affiliated health plans, today announced 45 distinguished medical practices and health systems to be honored in its annual Care Provider Recognition Program. The program spotlights the top one percent of primary care providers in Elevance Health's nationwide affiliated health plan network of about 7,200 value-based care and evaluated provider partners. The recognition highlights primary care providers who exhibit excellence in deliv.
Elevance Health's Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses
INDIANAPOLIS--(BUSINESS WIRE)--As small businesses continue to face rising healthcare costs, Elevance Health's affiliated health plans are delivering solutions that help employers offer competitive benefits, improve health outcomes, and keep costs more affordable and more predictable. Recent research shows small businesses and their employees have experienced healthcare cost increases of 26% over the past five years, underscoring the need for more stable and predictable solutions. Small busines.
Comerica Bank Sells 2,331 Shares of Elevance Health, Inc. $ELV
Comerica Bank lessened its holdings in Elevance Health, Inc. (NYSE: ELV) by 6.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,056 shares of the company's stock after selling 2,331 shares during the period. Comerica Bank's holdings
Centene Q1 Earnings Beat Estimates on Rising Premiums, 2026 View Up
CNC tops Q1 estimates on strong premiums, lifts 2026 outlook with higher revenue and EPS guidance despite membership decline and rising costs.
UHS' Q1 Earnings Beat on Strong Behavioral Health Care Admissions
Universal Health tops Q1 estimates as behavioral health admissions and patient days rise, driving revenue growth despite higher operating costs.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
Looking for broad exposure to the Healthcare - Healthcare - Providers segment of the equity market? You should consider the iShares U.S. Healthcare Providers ETF (IHF), a passively managed exchange traded fund launched on May 1, 2006.
Elevance Health Inc (ELV) Shares Surge 3.3% -- What GF Score of 76 Tells Investors
On April 27, 2026, Elevance Health Inc (ELV) shares rose 3.3% to $356.13, continuing a strong performance with a 1-week gain of 11.5% and a 1-month increase of
Cornerstone Investment Partners LLC Sells 2,136 Shares of Elevance Health, Inc. $ELV
Cornerstone Investment Partners LLC trimmed its position in Elevance Health, Inc. (NYSE: ELV) by 1.3% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 167,102 shares of the company's stock after selling 2,136 shares during the period. Elevance Health
ELV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Elevance Health, Inc.
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE:ELV) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
ELV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Elevance Health, Inc.
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
Price Targets
Elevance Health price target raised to $460 from $400 at UBS
$460.00
(was $389.82)
UBS
Elevance Health price target raised to $435 from $385 at Mizuho
$435.00
(was $402.27)
Mizuho Securities
Elevance Health upgraded to Buy from Hold at Deutsche Bank
$498.00
(was $402.27)
Deutsche Bank
Elevance Health price target raised to $399 from $396 at Guggenheim
$399.00
(was $346.29)
Guggenheim
Elevance Health price target raised to $408 from $393 at Barclays
$408.00
(was $346.29)
Barclays
Elevance Health price target raised to $364 from $357 at Leerink
$364.00
(was $346.21)
Leerink Partners
Elevance Health price target raised to $331 from $317 at Baird
$331.00
(was $328.20)
Robert W. Baird
Elevance Health price target lowered to $391 from $395 at Jefferies
$391.00
(was $323.05)
David Windley
·
Jefferies
Elevance (ELV) PT Lowered to $350 at Mizuho
$350.00
(was $282.68)
Ann Hynes
·
Mizuho Securities
Elevance Health downgraded to Sector Perform from Outperform at RBC Capital
$358.00
(was $341.83)
RBC Capital
Elevance Health price target lowered to $390 from $400 at Truist
$390.00
(was $341.29)
Truist Financial
Elevance (ELV) PT Lowered to $409 at Bernstein
$409.00
(was $340.68)
Craig-Hallum
Elevance (ELV) PT Lowered to $409 at Bernstein
$409.00
(was $340.68)
Piper Sandler
Elevance Health price target lowered to $409 from $431 at Bernstein
$409.00
(was $345.74)
Bernstein
Elevance Health price target lowered to $391 from $424 at Wells Fargo
$391.00
(was $346.98)
Wells Fargo
Elevance Health price target lowered to $393 from $404 at Barclays
$393.00
(was $346.98)
Barclays
Elevance Health price target lowered to $400 from $425 at UBS
$400.00
(was $345.27)
UBS
Elevance Health price target raised to $332 from $320 at Deutsche Bank
$332.00
(was $345.22)
Deutsche Bank
Elevance Health price target lowered to $396 from $414 at Guggenheim
$396.00
(was $341.85)
Jason Cassorla
·
Guggenheim
Elevance Health price target raised to $414 from $398 at Guggenheim
$414.00
(was $369.88)
Jason Cassorla
·
Guggenheim